← Back
Data updated: Mar 29, 2026
GSK
GSK Infectious DiseaseRespiratoryOncology
Big Pharma
GSK is a major pharmaceutical company focused on Infectious Disease, Respiratory, Oncology. Key products include NUCALA.
$38.4B
Revenue (2024)
$85.0B
Market Cap
-
Trials
67
Approved (2yr)
Key Drugs
NUCALA
mepolizumab
IL-5 5 indications · 2015
BENLYSTA
belimumab
BLyS 2 indications · 2011
ZEJULA
niraparib tosylate
PARP-1 3 indications · 2017
BLUJEPA
gepotidacin mesylate
2 indications · 2025
TRELEGY ELLIPTA
fluticasone furoate
Glucocorticoid receptor 2 indications · 2017
Top Drug Revenues Pro
Loading...
Revenue Over Time Pro
Loading...
Competitive Matchups Pro
Loading...
Loading...
Recent Activity
CEFAZOLIN SODIUM 2026-02-13
Efficacy
PHYTONADIONE 2026-01-09
EXDENSUR 2025-12-16
Type 1 - New Molecular Entity
BLUJEPA 2025-12-11
Efficacy
IMITREX STATDOSE 2025-12-09
Labeling
IMITREX 2025-12-09
Labeling
IMITREX 2025-12-09
Labeling
CEFAZOLIN SODIUM 2025-12-01
Manufacturing (CMC)
SEC Filings
Pro
Loading...
Therapeutic Areas
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Infectious Disease 33%
2 drugs Phase 3: 44 Phase 2: 31 Phase 1: 60
Respiratory 32%
11 drugs Phase 3: 31 Phase 2: 23 Phase 1: 66
Oncology 22%
3 drugs Phase 3: 20 Phase 2: 24 Phase 1: 59
Immunology 10%
2 drugs Phase 3: 6 Phase 2: 14 Phase 1: 30
Neurology 3%
4 drugs Phase 2: 2 Phase 1: 2
Pipeline Forecast
Loading...
Loading...
Upcoming Trial Milestones Pro
Loading...
Patent Cliff Pro
Loading...
Loading...
Loading...
Competitors by Therapeutic Area
AbbVie big-pharma
Immunology, Oncology, Neurology, Infectious Disease
Sanofi big-pharma
Oncology, Infectious Disease, Immunology, Respiratory
Roche big-pharma
Oncology, Neurology, Immunology, Respiratory
Bristol-Myers Squibb big-pharma
Oncology, Immunology, Infectious Disease, Neurology
Pfizer big-pharma
Oncology, Infectious Disease, Immunology
Active (37)
EXDENSUR BLENREP BLUJEPA OJJAARA BREXAFEMME JEMPERLI KRINTAFEL TRELEGY ELLIPTA ZEJULA NUCALA ARNUITY ELLIPTA INCRUSE ELLIPTA ANORO ELLIPTA BREO ELLIPTA BENLYSTA LAMICTAL XR LAMICTAL ODT ADVAIR HFA FLOVENT HFA LORATADINE VENTOLIN HFA FLOVENT DISKUS 250 FLOVENT DISKUS 50 FLOVENT DISKUS 100 ADVAIR DISKUS 500/50 ADVAIR DISKUS 100/50 ADVAIR DISKUS 250/50 MALARONE PEDIATRIC MALARONE RELENZA WELLBUTRIN SR VALTREX LAMICTAL SEREVENT IMITREX STATDOSE PHYTONADIONE LAROTID
Discontinued (90)
CEFAZOLIN SODIUM IMITREX ZOVIRAX WELLBUTRIN LAMICTAL CD AMOXIL JESDUVROQ EPIVIR-HBV FLOLAN REQUIP REQUIP XL ZYBAN CEFTIN DYAZIDE BACTROBAN ZANTAC 150 MEPRON BECONASE AQ SUDAFED 12 HOUR RYTHMOL RYTHMOL SR TANZEUM AMERGE POTIGA TIMENTIN IN PLASTIC CONTAINER TIMENTIN ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER ZANTAC 300 ZANTAC ZANTAC 25 VONTROL DARBID DEXEDRINE THRIVE NEOSPORIN TAGAMET POLYSPORIN RELAFEN AXID AGENERASE COMPAZINE DYNACIRC DYNACIRC CR ANCEF FLOVENT VENTOLIN TICAR BECONASE HALFAN CEPTAZ
+40 more
Company Info
- First Approval
- 1949-03-28
- Latest
- 2025-12-16
- Applications
- 173
FDA Sponsor Names
GLAXOSMITHKLINE CONSGLAXOSMITHKLINEGLAXO GRP ENGLANDSMITHKLINE BEECHAMGLAXOSMITHKLINE LLC +1